Skip to main content
. 2020 Oct 10;22(11):617–629. doi: 10.1016/j.neo.2020.09.004

Fig. 1.

Fig. 1

PRMT5 is upregulated in HNSCC and correlates with metastasis and patient survival. (A) Analysis of PRMT5 in HNSCC, ESCC, LUSCC and normal control in TCGA database. (Student’s t-test). (B) Representation and quantification of IHC staining of normal oral mucosa (n = 36), dysplasia tissues (n = 30) and HNSCC tissues (n = 104) using anti-PRMT5. Scale bar, 50 μm, 20 μm. (Chi-Square test). (C) Representation and quantification of IHC staining of normal oral mucosa (n = 9), dysplasia tissues (n = 6) and cancer tissues (n = 15) of rats using anti-PRMT5. Scale bar, 50 μm, 20 μm. (Chi-Square test). (D) Quantification of PRMT5 protein levels according to IHC scores in N-regional lymph nodes metastatic HNSCC tissues (n = 31) and non-metastatic HNSCC tissues (n = 62). (Student’s t test). (E) Kaplan–Meier overall survival curve of PRMT5 for HNSCC patients (n = 68) (cut-off value: score = 2). (log-rank test). (F) Kaplan–Meier overall survival curve of PRMT5 for HNSCC patients (n = 486) in TCGA database (cut-off value:11.594). (log-rank test).